Literature DB >> 30948419

Dynamic morphological changes in Libman-Sacks endocarditis under different anticoagulation regimens.

Takaya Kitano1, Kaoruko Sengoku2, Eri Itotagawa3, Kenichi Todo1.   

Abstract

Entities:  

Keywords:  connective tissue disease; immunology; neurology (drugs and medicines); stroke; valvar diseases

Mesh：

Substances：

Year:  2019        PMID： 30948419      PMCID： PMC6453425          DOI： 10.1136/bcr-2019-229909

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


× No keyword cloud information.
  5 in total

1.  Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome.

Authors:  M A Agirbasli; D E Hansen; B F Byrd
Journal:  J Am Soc Echocardiogr       Date:  1997-10       Impact factor: 5.251

Review 2.  Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.

Authors:  M Hojnik; J George; L Ziporen; Y Shoenfeld
Journal:  Circulation       Date:  1996-04-15       Impact factor: 29.690

Review 3.  Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.

Authors:  Virginie Dufrost; Jessie Risse; Tatiana Reshetnyak; Maria Satybaldyeva; Yao Du; Xin-Xin Yan; Stella Salta; Grigorios Gerotziafas; Zhi-Cheng Jing; Ismaël Elalamy; Denis Wahl; Stéphane Zuily
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

4.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Authors:  Vittorio Pengo; Gentian Denas; Giacomo Zoppellaro; Seena Padayattil Jose; Ariela Hoxha; Amelia Ruffatti; Laura Andreoli; Angela Tincani; Caterina Cenci; Domenico Prisco; Tiziana Fierro; Paolo Gresele; Arturo Cafolla; Valeria De Micheli; Angelo Ghirarduzzi; Alberto Tosetto; Anna Falanga; Ida Martinelli; Sophie Testa; Doris Barcellona; Maria Gerosa; Alessandra Banzato
Journal:  Blood       Date:  2018-07-12       Impact factor: 22.113

5.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Authors:  Hannah Cohen; Beverley J Hunt; Maria Efthymiou; Deepa R J Arachchillage; Ian J Mackie; Simon Clawson; Yvonne Sylvestre; Samuel J Machin; Maria L Bertolaccini; Maria Ruiz-Castellano; Nicola Muirhead; Caroline J Doré; Munther Khamashta; David A Isenberg
Journal:  Lancet Haematol       Date:  2016-09       Impact factor: 18.959
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.